Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Next Previous
X
Search
Trial Profile

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs P-BCMA-ALLO1 (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Poseida Therapeutics

    • Most Recent Events

    • 09 Dec 2024 According to Poseida Therapeutics media release, data from this study presented at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024.
    • 09 Dec 2024 Results published in the Poseida Therapeutics Media Release.
    • 14 Nov 2024 According to Poseida Therapeutics media release, data company ill provide an overview of recently reported interim Phase 1 results from this study at virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top